RecruitingNCT07699445
Lumateperone and obesity, biological aging, and antidepressant response in bipolarity
About this title
The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar Depression
Read the official source — NCT07699445Researchers are studying Lumateperone 42 mg to find out how it affects depression symptoms in people with bipolarity during a depressive episode.
Medication studyAges 18–65United States
Understand this study
What is this study about?
Researchers are studying Lumateperone 42 mg to find out how it affects depression symptoms in people with bipolarity during a depressive episode.
Who could participate?
This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
You take lumateperone 42 mg orally each day for about six weeks. The study includes an MRI (magnetic resonance imaging) scan at the start and examines mood symptoms and inflammation in people living with bipolarity.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Participation duration
- Daily lumateperone treatment lasts about 6 weeks; an MRI (magnetic resonance imaging) is planned at the start.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 9, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 25
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07699445
- Official title
Show the full official title
The Effects of Lumateperone on Obesity and Physiologic Aging and Their Correlation With Antidepressant Response in Bipolar Depression
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Boston
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are studying Lumateperone 42 mg to find out how it affects depression symptoms in people with bipolarity during a depressive episode.
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Lumateperone 42 mg.
Who can participate?
This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
